“The existing problem has exposed some structural weaknesses while in the EU’s medicines provide chain plus a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She encouraged that provide chain issues be addressed in an EU pharmaceutical tactic anticipated to become introduc